Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cystine→

Cystine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
56-89-3
Molecular formula
C6H12N2O4S2
Molecular weight
240.3 g/mol
Drug class
Disulfide-linked dimer of cysteinesulfur-containing amino acid
Mechanism of action
Cystine is reduced intracellularly to cysteine, which contributes to protein synthesis and glutathione biosynthesis. It is a nutritional amino acid rather than a conventional drug with one receptor-mediated therapeutic mechanism.
Indications / reported uses
  • Nutritional amino-acid component in selected supplements and medical nutrition products; no broad standalone therapeutic indication should be assigned. Cystine is also relevant to cystinuria and cystine-stone biology, but oral cystine is not a treatment for cystinuria.

Sources: NLM MeSH — Cystine · PubChem — L-Cystine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cystine Environmental Risk Assessment (ERA) (the Cystine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.